Vitreoretinal lymphoma

Bianka Sobolewska, Soon Phaik Chee, Fatma Zaguia, Debra Anne Goldstein, Justine R. Smith, Falko Fend, Manabu Mochizuki, Manfred Zierhut

Research output: Contribution to journalReview articlepeer-review

Abstract

Vitreoretinal lymphoma (VRL) is a rare variant of primary central nervous system lymphoma (PCNSL), mostly of diffuse large B cell lymphoma, which affects the retina and/or the vitreous with or without optic nerve involvement. The disease course is aggressive. Up to 90% of the patients develop central nervous system lymphoma within one year. The diagnosis of VRL is challenging due to nonspecific chronic and relapsing uveitis and is made by anterior chamber tab or vitreous aspirate biopsy. There is no established treatment protocol for VRL patients with bilateral involvement without CNS involvement. There are suggestions to use only intravitreal chemotherapy with methotrexate and/or rituximab. Alternatively, systemic high-dose MTX treatment or external beam radiotherapy is used. Further studies are needed to prove and confirm the prophylactic systemic therapy in preventing CNS involvement in limited VRL.

Original languageEnglish
Article number3921
Number of pages23
JournalCancers
Volume13
Issue number16
DOIs
Publication statusPublished - 2 Aug 2021

Keywords

  • CNS lymphoma
  • IL-10/IL-6 ratio
  • Methotrexate
  • MYD88
  • Vitreoretinal lymphoma

Fingerprint

Dive into the research topics of 'Vitreoretinal lymphoma'. Together they form a unique fingerprint.

Cite this